Antidiabetic bicyclic compounds

US9840512B2 · kind B2 · utility

Assignee

• Merck Sharp & Dohme LLC · US

Inventors

• Linda Brockunier · Orange, US
• Helen Chen · Livingston, US
• Harry R. Chobanian · Kenilworth, US
• Matthew J. Clements · Old Bridge, US
• Alejandro Crespo · Edison, US
• Duane DeMong · Somerville, US
• Yan Guo · Westfield, US
• William K. Hagmann · Westfield, US
• Karen Marcantonio · New York, US
• Michael Miller · Scotch Plains, US
• Barbara Pio · West Orange, US
• Christopher W. Plummer · Hoboken, US
• Dong Xiao · Hackettstown, US

Key dates

• Filing date: Feb 20, 2014
• Grant date: Dec 12, 2017
• Expiry date: Feb 20, 2034

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D491/052
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are agonists of G-protein coupled receptor 40 (GPR40) and may be useful in the treatment, prevention and suppression of diseases mediated by the G-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia.